<DOC>
	<DOCNO>NCT01376349</DOCNO>
	<brief_summary>RATIONALE : Dehydroepiandrosterone ( DHEA ) may help relieve vaginal symptom female cancer survivor . PURPOSE : This randomized phase III trial study DHEA see well work compare placebo treat postmenopausal cancer survivor vaginal symptom .</brief_summary>
	<brief_title>Prasterone ( Dehydroepiandrosterone ) Treating Postmenopausal Cancer Survivors With Vaginal Symptoms</brief_title>
	<detailed_description>Primary Goal : - To determine effectiveness two dos daily vaginal prasterone ( dehydroepiandrosterone [ DHEA ] ) versus placebo alleviation bothersome vaginal symptom ( vaginal dryness dyspareunia ) 12 week . Exploratory Goals : - To evaluate toxicity arise DHEA patient population . ( Exploratory ) - To evaluate impact vaginal DHEA negative sexual thought , sexual function urologic symptom . ( Exploratory ) - To explore role psychologic ( mood , stress ) , physical ( demographic treatment variable ) situational factor ( partner variable fatigue ) predictor vaginal dryness performance outcome baseline various endpoint throughout study . ( Exploratory ) - To explore characteristic vaginal atrophy relationship vaginal atrophy quality-of-life questionnaire response exposure hormonal therapy ( tamoxifen , exemestane , anastrozole , letrozole ) . ( Exploratory ) - To examine effect use open-label vaginal DHEA gel 8 week woman complete placebo gel arm randomize trial . ( Exploratory ) Correlative Research Goals : - To evaluate impact vaginal DHEA maturation index pH ( select institution ) . - To evaluate impact vaginal DHEA sex steroid concentration ( estradiol , free testosterone , estrone , DHEA-S ) marker bone turnover ( osteocalcin bone alkaline phosphatase ) . ( Correlative ) - As part ongoing research NCCTG Cancer Control study , bank blood product future study . ( Correlative ) OUTLINE : This multicenter study . Patients stratify accord current tamoxifen therapy ( yes v ) , concurrent aromatase inhibitor use ( anastrozole/letrozole v exemestane v none ) , hysterectomy ( yes v ) , cigarette smoking ( current v past v never ) . Patients randomize 1 3 treatment arm , patient receive low dose vaginal DHEA , high dose vaginal DHEA vaginal placebo gel . Participants may complete Profile Mood States ( POMS ) , Perceived Stress Scale ( PSS ) , Fatigue : Vitality subscale SF-36 , Vaginal Symptom Quality Questionnaire , DHEA Side Effect Questionnaire , Female Sexual Function Index ( FSFI ) , Sexually Related Intrusive Thoughts - ITS , Impact Treatment Scale , Urogenital Atrophy Questionnaire , Subject Global Impression Change baseline periodically study .</detailed_description>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>1 . Age ≥ 18 year 2 . Postmenopausal woman history breast gynecologic cancer ( currently evidence disease ) . Note : Postmenopausal status determine follow criterion : 1 . 12 month without period bilateral oophorectomy complete chemical ovarian suppression past 12 month continue suppression plan throughout course study 2. menopausal status determine FSH estradiol value postmenopausal range ( generally FSH &gt; 40IU/L estradiol &lt; 10 pg/ml , depend laboratory ) : 9 month without period post hysterectomy least one ovary remain less 55 year old . Note : age 55 old criterion , menopausal status need determine labs 3 . Significant vaginal complaint . Note : Defined persistent vaginal dryness and/or pain intercourse ( dyspareunia ) sufficient severity make patient desire therapeutic intervention . 4 . Eligibility questionnaire response must moderate bad level severity one two symptom , either dryness dyspareunia . The protocol contain information . 5 . Vaginal symptom must present ≥ 2 month prior randomization . 6 . Life expectancy &gt; 12 month . 7 . Ability complete questionnaire assistance . 8 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 . 9 . The patient must provide informed write consent . 10 . Willing return enrol institution followup . 11 . Willing provide blood sample correlative research purpose . 1 . Initiation discontinuation tamoxifen aromatase inhibitor ≤ 2 month prior randomization plan initiate discontinue medication 12week study . 2 . Current diagnosis active vaginal infection , symptoms vaginal infection , must rule ( ie , foul discharge , fever ) . 3 . Concurrent chemotherapy ( long term adjuvant herceptin , lapatanib , and/or bevacizumab allow . 4 . Planned use vaginal preparation study period ( include counter herbal preparation ) . Note : Waterbased lubricant ( KY jelly ) allow sexual intercourse . 5 . Use daily nonhormonal vaginal preparation ≤ 1 week prior study entry . Exception : Daily waterbased lubricant sexual intercourse . Note : Patients stop agent may enrol one week . 6 . Current ( ≤ 4 week prior randomization ) , plan study period , use estrogen product kind hormonal vaginal product include bioidentical hormone , estriol androgen product . 7 . Use pharmacologic soy phytoestrogen preparation ( Dietary intake soy ie milk acceptable ) . 8 . On placebo control trial endocrine therapy . 9 . Prior concurrent pelvic radiation therapy . 10 . Prior radical pelvic surgery , specifically vaginectomy pelvic exenteration ( TAH/BSO ) allow ) . 11 . Diagnosis follow condition within past five year : 1 . Essential vulvodynia 2 . Vulvar vestibulitis 3 . Bartholin cyst/abscess 4 . History Bartholin gland surgery 5 . Lichen sclerosis 6 . Lichen planus vulvovaginal region 7 . Desquamative vaginitis 12 . History current diagnosis follow condition : 1 . Vulvar vaginal dysplasia 2 . Vaginal prolapse 13 . Women childbearing potential , premenopausal woman .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>depression</keyword>
	<keyword>anxiety disorder</keyword>
	<keyword>cognitive/functional effect</keyword>
	<keyword>sexual dysfunction</keyword>
	<keyword>cancer survivor</keyword>
	<keyword>breast cancer</keyword>
	<keyword>cervical cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>uterine sarcoma</keyword>
	<keyword>vaginal cancer</keyword>
	<keyword>vulvar cancer</keyword>
	<keyword>ovarian epithelial cancer</keyword>
	<keyword>ovarian germ cell tumor</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>ovarian stromal cancer</keyword>
	<keyword>primary peritoneal cavity cancer</keyword>
	<keyword>endometrial cancer</keyword>
</DOC>